All In Biotech

Drug Trial Radar · NCT00605215

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design

Last checked: Nov 20, 2026Latest source record: Apr 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,331 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,331

Actual

Start

Apr 24, 2008

Primary completion

Jun 10, 2011

Study completion Jun 10, 2011

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).

Conditions

  • Multiple Sclerosis

Interventions

  • LaquinimodDrug

    Laquinimod will be administered per dose and schedule specified in the arm description.

  • PlaceboDrug

    Placebo matching to laquinimod will be administered per schedule specified in the arm description.

  • Avonex®Drug

    Avonex® will be administered per dose and schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Confirmed RelapsesTime frame: Baseline up to Month 24

Locations

170 sites in 19 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 1267

    Birmingham, Alabama

  • Teva Investigational Site 1237

    Phoenix, Arizona

  • Teva Investigational Site 1252

    Phoenix, Arizona

  • Teva Investigational Site 1279

    Phoenix, Arizona

  • Teva Investigational Site 1276

    Tucson, Arizona

  • Teva Investigational Site 1272

    Pasadena, California

  • Teva Investigational Site 1238

    Sacramento, California

  • Teva Investigational Site 1280

    Aurora, Colorado

  • Teva Investigational Site 1255

    Orlando, Florida

  • Teva Investigational Site 1282

    Sarasota, Florida

  • Teva Investigational Site 1275

    Atlanta, Georgia

  • Teva Investigational Site 1250

    Peoria, Illinois

  • Teva Investigational Site 1260

    Indianapolis, Indiana

  • Teva Investigational Site 1268

    Lenexa, Kansas

  • Teva Investigational Site 1277

    New Orleans, Louisiana

  • Teva Investigational Site 1263

    Shreveport, Louisiana

  • Teva Investigational Site 1269

    Baltimore, Maryland

  • Teva Investigational Site 1274

    Grand Rapids, Michigan

  • Teva Investigational Site 1239

    Lebanon, New Hampshire

  • Teva Investigational Site 1265

    Teaneck, New Jersey

  • Teva Investigational Site 1273

    Albany, New York

  • Teva Investigational Site 1264

    Amherst, New York

  • Teva Investigational Site 1283

    Cedarhurst, New York

  • Teva Investigational Site 1249

    Raleigh, North Carolina

  • Teva Investigational Site 1262

    Winston-Salem, North Carolina

  • Teva Investigational Site 1261

    Akron, Ohio

  • Teva Investigational Site 1241

    Canton, Ohio

  • Teva Investigational Site 1245

    Cleveland, Ohio

  • Teva Investigational Site 1247

    Columbus, Ohio

  • Teva Investigational Site 1244

    Portland, Oregon

  • Teva Investigational Site 1258

    Philadelphia, Pennsylvania

  • Teva Investigational Site 1281

    Nashville, Tennessee

  • Teva Investigational Site 1284

    San Antonio, Texas

  • Teva Investigational Site 1248

    Richmond, Virginia

  • Teva Investigational Site 1270

    Roanoke, Virginia

  • Teva Investigational Site 1253

    Tacoma, Washington

  • Teva Investigational Site 5914

    Pleven, Bulgaria

  • Teva Investigational Site 5915

    Pleven, Bulgaria

  • Teva Investigational Site 5917

    Plovdiv, Bulgaria

  • Teva Investigational Site 4212

    Rousse, Bulgaria

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.